Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Study Design in Statistics01:15

Study Design in Statistics

9.9K
A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
9.9K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

581
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
581
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

341
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
341

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients.

Molecular oncology·2026
Same author

Boosting the Power of Rare Variant Association Studies by Imputation Using Large-scale Sequencing Population.

Genomics, proteomics & bioinformatics·2025
Same author

Impact of Cement Distribution on the Efficacy of Percutaneous Vertebral Augmentation for Osteoporotic Fractures: Assessment with an MRI-Based Reference Marker.

The Journal of bone and joint surgery. American volume·2025
Same author

A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer.

Molecular oncology·2024
Same author

Associations of ambient air pollution and lifestyle with the risk of NAFLD: a population-based cohort study.

BMC public health·2024
Same author

Checkpoint Kinase 1 Stimulates Endogenous Cardiomyocyte Renewal and Cardiac Repair by Binding to Pyruvate Kinase Isoform M2 C-Domain and Activating Cardiac Metabolic Reprogramming in a Porcine Model of Myocardial Ischemia/Reperfusion Injury.

Journal of the American Heart Association·2024

Related Experiment Video

Updated: Jan 18, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K

Bayesian sequential decision-making for rare disease clinical trials.

Yuan Gao1, Jianling Bai1, Feng Chen1

  • 1Department of Biostatistics, School of Public Heath, Nanjing Medical University, Nanjing, China.

Technology and Health Care : Official Journal of the European Society for Engineering and Medicine
|May 29, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian sequential design for rare disease clinical trials. It allows for earlier stopping of trials for superiority or futility, saving time, costs, and preventing patient exposure to ineffective treatments.

Keywords:
Bayes FactorBayes Factor Design AnalysisBayesian sequential decisionSequential Bayes Factor Testrare disease clinical trials

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Drug Development

Background:

  • Rare disease clinical trials face significant challenges, including small patient populations and the ethical need to avoid futile treatments.
  • Traditional fixed-sample trial designs are often inefficient for rare diseases.
  • Bayesian sequential design offers a dynamic approach to optimize decision-making under uncertainty.

Purpose of the Study:

  • To propose and evaluate a novel Bayesian sequential design framework for rare disease clinical trials.
  • To enable earlier and more efficient trial termination based on accumulating evidence.
  • To reduce sample size, duration, and costs while ensuring patient safety and interpretable results.

Main Methods:

  • Integration of sequential Bayes factor analysis with adaptive stopping rules for binary endpoints.
  • Utilization of Bayesian posterior probabilities to establish early termination thresholds for superiority or futility.
  • Application of Bayes Factor Design Analysis to ensure trial feasibility and guide interim decisions.

Main Results:

  • The proposed Bayesian sequential design facilitates earlier trial cessation for both demonstrated efficacy (superiority) and lack thereof (futility).
  • Significant reductions in sample size, trial duration, and financial expenditure are achievable.
  • Patient exposure to treatments lacking efficacy is minimized, enhancing ethical trial conduct.

Conclusions:

  • The Bayesian sequential design accelerates the confirmation of treatment efficacy in rare diseases, allowing prompt trial closure.
  • This approach optimizes resource allocation and enhances patient welfare by avoiding prolonged exposure to non-beneficial therapies.
  • Promoting Bayesian sequential decision-making can expedite rare disease drug approvals and market access.